Undisclosed Program

About Maze Therapeutics

Maze Therapeutics is a biotechnology company that maps the connections between genetic variants and disease to develop novel therapeutics. The company's core Compass platform integrates human genetics, functional genomics, and data science to identify protective genetic modifiers, which serve as blueprints for drug development. Maze has advanced its lead candidate, MZE001 for APOL1-mediated kidney disease, into Phase 2 clinical trials and secured significant funding, including a $190 million Series C and a strategic partnership with Sanofi. The company aims to build a pipeline of precision medicines for patients with high unmet need.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals aims to decode biology and radically improve lives by applying artificial intelligence and automation to drug discovery. Its core asset is the Recursion OS, a comprehensive platform that generates and analyzes petabytes of proprietary biological data to fuel an internal pipeline of potential first-in-class and best-in-class therapies. The company has advanced several programs into clinical trials, secured strategic partnerships with industry leaders, and is building one of the most powerful supercomputers in biopharma to scale its operations.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals aims to decode biology and radically improve lives by applying artificial intelligence and automation to drug discovery. Its core asset is the Recursion OS, a comprehensive platform that generates and analyzes petabytes of proprietary biological data to fuel an internal pipeline of potential first-in-class and best-in-class therapies. The company has advanced several programs into clinical trials, secured strategic partnerships with industry leaders, and is building one of the most powerful supercomputers in biopharma to scale its operations.

About Relay Therapeutics

Relay Therapeutics is redefining drug discovery by focusing on the dynamic nature of proteins, moving beyond static structures to understand how protein motion influences function and disease. Its proprietary Dynamo platform combines computational structural biology, machine learning, and experimental techniques to identify novel drug targets and allosteric sites. The company has advanced a pipeline of precision oncology candidates, most notably RLY-4008, a highly selective FGFR2 inhibitor, and is building a robust portfolio targeting validated oncogenes with next-generation specificity. Relay's approach aims to create best-in-class therapies with improved safety and efficacy profiles.

About Pharming Group

Pharming Group is a commercial-stage rare disease biopharmaceutical company with a mission to transform the lives of underserved patients. The company leverages its proven clinical development, supply chain, and commercial infrastructure to grow its existing portfolio and invest in long-term pipeline expansion. With a dual listing on Euronext Amsterdam (PHARM) and Nasdaq (PHAR), Pharming aims to become a leading global rare disease company through a combination of organic growth and strategic business development.

About uniQure

uniQure is a clinical-stage gene therapy company with over two decades of experience, dedicated to reimagining medicine through innovative genomic treatments. The company has built a modular AAV platform, featuring proprietary technologies like miQURE for gene silencing, and is advancing a pipeline targeting CNS and liver diseases. With a lead program, AMT-130, in late-stage development for Huntington's disease and a commercial-stage partnership for hemophilia B gene therapy, uniQure is positioned at the forefront of the gene therapy revolution.

About MapLight Therapeutics

MapLight Therapeutics is focused on transforming the treatment of brain disorders by developing precision medicines that target specific dysfunctional neural circuits. The company's MAP (Molecular and Anatomical Phenotyping) platform integrates advanced neuroscience tools to deconstruct complex behaviors and identify novel therapeutic targets. With a lead program in Phase 2 for autism spectrum disorder and a pipeline of preclinical candidates, MapLight is advancing a new generation of neuropsychiatric drugs. The company went public in 2024 and is positioned to address significant unmet needs in neurology and psychiatry.

About Sangamo Therapeutics

Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.

About Sangamo Therapeutics

Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.

About Sangamo Therapeutics

Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.

About Sangamo Therapeutics

Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.

About Cocrystal Pharma

Cocrystal Pharma is focused on discovering and developing first- and best-in-class antiviral drugs that target the viral replication machinery. The company's unique technology platform, guided by Nobel laureate Dr. Roger Kornberg, enables the efficient design of inhibitors against proteases and polymerases. With multiple programs advancing through clinical trials, including oral and inhaled candidates for influenza and a dual coronavirus-norovirus protease inhibitor, Cocrystal aims to address significant unmet needs in antiviral treatment with drugs designed to be safe, convenient, and resistance-resistant.

Therapeutic Areas